Chocolate delights | Software delays | Scientific excellence
An encouraging update from the French named but UK created chocolatier lifts its share price, but the valuation looks very rich to us. Elsewhere, a scientific instrument specialist continues to impress while a software group focused on the US healthcare market was more cautious. Read on here for the latest news from AIM.
Craneware: recovery taking longer than anticipated
Craneware (AIM: CRW), the market leader in Value Cycle solutions for the US healthcare market, issued a somewhat disappointing trading update for the six months ending 31 December 2022.
Group revenues in the period are expected to increase by 6% to approximately $84.7m (H1 FY22: $80.2m) with adjusted EBITDA up 8% to $25.5m.
Software revenues remain robust and continue to recover from the pandemic, however, Professional…
Sign up and read the full article
Register to continue reading our content.
Already a member? Login
Previous article Next article